Wen-Ting Hsieh

Wen-Ting Hsieh

Auto-generated profile, based on publicly available information

Wen-Ting Hsieh

MacKay Mem Hosp, Biomed Res & Innovat Incubat Ctr, 9F,96 Chia Hsin Bldg,2nd Bldg,Sec 2, Taipei 10449, Taiwan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Acta Biomaterialia
Verified
Journal Article
Closed access
WHWen-Ting Hsieh
Wen-Ting Hsieh
YLYi-Shiuan Liu
Yi-Shiuan Liu
YLYi-Hsuan Lee
Yi-Hsuan Lee
MRMarilyn G. Rimando
Marilyn G. Rimando
KLKeng-Hui Lin
Keng-Hui Lin
OLOscar K. Lee
Oscar K. Lee

2 November 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CSChia-Hsin Su
Chia-Hsin Su
ILI-Hsuan Lin
I-Hsuan Lin
TTTsai-Yu Tzeng
Tsai-Yu Tzeng
WHWen-Ting Hsieh
Wen-Ting Hsieh
MHMing-Ta Hsu
Ming-Ta Hsu
Cytokines are low molecular weight regulatory proteins, or glycoproteins, with both tumor-promoting and inhibitory effects on breast cancer growth. Different cytokines play important roles in breast cancer initiation and progression. Here, we show that of the 39 interleukin (IL) genes, IL-20 is the only gene over-expressed in MCF-7 cells treated with estradiol (E2) and that induction of IL-20 expression by estrogen was epigenetically regulated. Methylation of histone H3K4 in the IL-20 promoter was shown to occur via the specific recruitment of KMT2B by estrogen receptor alpha (ERα), but not by other members of the mixed-lineage leukemia (MLL) family of histone methyltransferases. Depletion of KMT2B, or IL-20, disrupts estrogen signaling, attenuates cell proliferation, reduces colony formation, and results in cell cycle arrest. Furthermore, we demonstrated that KMT2B-mediated epigenetic modification also affected the expression of several ERα target genes. IL-20 and KMT2B expression were also associated with ERα-positive breast cancer tissues. We have revealed an important role for KMT2B in the epigenetic transcriptional regulation of cytokine IL-20, and other ERα-responsive genes, in breast cancer cells. Inhibition of IL-20 and KMT2B may have therapeutic benefits in ERα-positive breast cancer.

3 July 2018 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
WHWen-Ting Hsieh
Wen-Ting Hsieh
YSYung-Cheng Su
Yung-Cheng Su
HHHsin-Lien Han
Hsin-Lien Han
MHMing-Yuan Huang
Ming-Yuan Huang
Background: Mobile health (mHealth) apps have recently demonstrated the potential to engage and empower people to improve their own health. Although the availability of health-related apps is increasing, their adoption rate in Taiwan is exceptionally low mainly due to the preponderance of Western culture-based app designs that are challenging for non-English-speaking individuals. To our knowledge, no mHealth app is available in Taiwan that is culturally tailored for Chinese-speaking users and that applies a patient-centered approach to self-manage medication and health. Objective: The purpose of this study was to design and deploy a culturally tailored mHealth system that could be easily integrated into current clinical practice and to evaluate how this mHealth system could support the continuity of patient care in Taiwan. Methods: An mHealth information system and a mobile app were designed. To promote the best patient experience, a Quick Response (QR) code system was developed to enable efficient registration of personal medication information through the mobile app. The app also supported notifications for drug utilization, refills, and symptom checks. Patients were encouraged to record medication use, symptoms, and self-assessments in the app during their treatment period. Evaluation of the novel mHealth system was conducted from August 1, 2016 to December 31, 2016 at MacKay Memorial Hospital, Taipei, Taiwan. Population data and app usage statistics were analyzed. Results: During the 5-month implementation period, a total of 25,909 users downloaded the app with an overall 7-day retention rate of 15.4% (SD 3.9). Young male adults (range 25-44 years) were the predominant user population. Patients’ feedback on app usability and design, QR code system as drug input method, medication reminders, and linking family or friends into care networks was generally positive. Physicians showed great interest in utilizing patient-generated data in their care process, and the positive medication adherence rate was the most highly valued component of this system. Conclusions: This pilot study demonstrated the value of a novel mHealth approach for individualized medication and health management in Taiwan. The mHealth system shows the potential to optimize personalized care into existing clinical services and may help hospitals and health authorities perform continuous quality improvement and policy development.

28 June 2021 in Journal of the Chinese Medical Association
Verified
Journal Article
Open access
CCChi-Lu Chiang
Chi-Lu Chiang
WHWen-Ting Hsieh
Wen-Ting Hsieh
CTChao-Hsiun Tang
Chao-Hsiun Tang
MSMeei-Ling Sheu
Meei-Ling Sheu
YCYuh-Min Chen
Yuh-Min Chen
Background: Small cell lung cancer (SCLC) is the most aggressive form of lung cancer. The chemotherapy regimens and their efficacy in practice are seldom reported. We aimed to investigate treatment patterns and survival outcomes of patients with SCLC in Taiwan. Methods: Patients newly diagnosed with SCLC from 2011 to 2015 were identified from the Cancer Registry database. Their clinical characteristics, treatment regimens, and survival status were obtained from National Health Insurance Research database. The Kaplan–Meier method and Cox-proportional hazard model were used to analyze the survival outcomes. Results: Among a total of 2707 patients enrolled, 439 were in the limited stage (LS, 16.22%) and 2268 were in the extensive stage of the disease (ES, 83.78%). The median age was 66 and the majority were male (90.36%). The first-line regimen used for the patients was etoposide/cisplatin-based treatment, followed by etoposide/carboplatin-based regimen, and etoposide only. The median overall survival (OS) was 16.92 months (95% confidence interval [CI] 15.31–18.92) and 8.71 months (95% CI 8.38–9.07) in LS and ES patients, respectively. Chemotherapy regimen, Eastern Cooperative Oncology Group performance status, and history of radiotherapy were significant factors associated with OS. On the other hand, the major second-line treatment was a topotecan-based regimen (68.3%). However, this showed inferior survival outcome compared to etoposide-based regimen (5.09 months [95% CI 4.76–5.62] versus 8.77 months [95% CI 6.31–11.89], p < 0.001). Conclusion: Etoposide is the preferred and superior first-line chemotherapy regimen in combination with platinum, and an alternative choice of second-line regimen for Taiwanese patients with SCLC.

20 January 2021 in JMIR Preprints
Verified
Preprint
Open access
WHWen-Ting Hsieh
Wen-Ting Hsieh
YSYung-Cheng Su
Yung-Cheng Su
HHHsin-Lien Han
Hsin-Lien Han
MHMing-Yuan Huang
Ming-Yuan Huang
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).

30 January 2018 in JMIR Preprints
Verified
Preprint
Open access
WHWen-Ting Hsieh
Wen-Ting Hsieh
YSYung-Cheng Su
Yung-Cheng Su
HHHsin-Lien Han
Hsin-Lien Han
MHMing-Yuan Huang
Ming-Yuan Huang
BACKGROUND Mobile health (mHealth) apps have recently demonstrated the potential to engage and empower people to improve their own health. Although the availability of health-related apps is increasing, their adoption rate in Taiwan is exceptionally low mainly due to the preponderance of Western culture-based app designs that are challenging for non-English-speaking individuals. To our knowledge, no mHealth app is available in Taiwan that is culturally tailored for Chinese-speaking users and that applies a patient-centered approach to self-manage medication and health. OBJECTIVE The purpose of this study was to design and deploy a culturally tailored mHealth system that could be easily integrated into current clinical practice and to evaluate how this mHealth system could support the continuity of patient care in Taiwan. METHODS An mHealth information system and a mobile app were designed. To promote the best patient experience, a Quick Response (QR) code system was developed to enable efficient registration of personal medication information through the mobile app. The app also supported notifications for drug utilization, refills, and symptom checks. Patients were encouraged to record medication use, symptoms, and self-assessments in the app during their treatment period. Evaluation of the novel mHealth system was conducted from August 1, 2016 to December 31, 2016 at MacKay Memorial Hospital, Taipei, Taiwan. Population data and app usage statistics were analyzed. RESULTS During the 5-month implementation period, a total of 25,909 users downloaded the app with an overall 7-day retention rate of 15.4% (SD 3.9). Young male adults (range 25-44 years) were the predominant user population. Patients’ feedback on app usability and design, QR code system as drug input method, medication reminders, and linking family or friends into care networks was generally positive. Physicians showed great interest in utilizing patient-generated data in their care process, and the positive medication adherence rate was the most highly valued component of this system. CONCLUSIONS This pilot study demonstrated the value of a novel mHealth approach for individualized medication and health management in Taiwan. The mHealth system shows the potential to optimize personalized care into existing clinical services and may help hospitals and health authorities perform continuous quality improvement and policy development.